Privately held biotechnology company developing small-molecule, oral, host-targeted antiviral therapeutics for infectious diseases
Privately held biotechnology company developing small-molecule, oral, host-targeted antiviral therapeutics for infectious diseases. Its lead candidate SLV213 inhibits host-cell cysteine proteases, including cathepsin L, to block viral entry. It has been studied against SARS-CoV-2 and variants, Ebola, Nipah, Marburg, and Chagas disease, and has advanced to clinical testing for COVID-19.